GLP-1 Receptor Agonists in Oncology from the 2026 ASCO Annual Meeting

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide and tirzepatide, have transformed the treatment of obesity and type 2 diabetes. At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, emerging evidence suggested these medications may also have an important role in oncology. Although none of the presented studies established causation, several large observational analyses demonstrated an association between GLP-1 RA use and improved cancer-related outcomes.

The most notable presentation, led by investigators from the Cleveland Clinic, evaluated more than 12,000 patients with stage I–III obesity-related cancers. Compared with patients receiving DPP-4 inhibitors, those treated with GLP-1 receptor agonists experienced significantly lower rates of progression to metastatic (stage IV) disease in several malignancies. The greatest reductions were observed in non-small cell lung cancer (approximately 50%), breast cancer (43%), colorectal cancer (31%), and hepatocellular carcinoma (38%). Favorable trends were also seen in pancreatic, prostate, and renal cancers, although these findings did not reach statistical significance.

Researchers also analyzed tumor gene-expression data and found that higher GLP-1 receptor expression was associated with improved overall survival across multiple cancer types. This observation raises the possibility that GLP-1 signaling may directly influence tumor biology in addition to improving metabolic health. However, the exact biological mechanisms remain uncertain. Proposed mechanisms include reductions in chronic inflammation, improvements in insulin resistance, favorable immune modulation, and changes within the tumor microenvironment.

Additional ASCO presentations suggested that GLP-1 receptor agonists may be associated with a lower incidence of breast cancer in women with overweight or obesity, improved outcomes among patients receiving immune checkpoint inhibitors, and reduced mortality in patients with hormone receptor-positive, HER2-negative metastatic breast cancer receiving CDK4/6 inhibitor therapy. These findings remain hypothesis-generating and require confirmation through prospective randomized clinical trials.

Overall, ASCO 2026 highlighted GLP-1 receptor agonists as a promising area of oncology research. While current evidence does not support prescribing GLP-1 medications specifically as anticancer therapy, the consistency of the observed associations across multiple tumor types has generated substantial interest. Future randomized trials will determine whether these medications can be incorporated into cancer prevention strategies or as adjunctive therapies alongside standard oncology treatments.